|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes显示文摘This review aims to outline the most up-to-date knowledge of pancreatic adenocarcinoma risk, diagnostics, treatment and outcomes, while identifying gaps that aim to stimulate further research in this understudied malignancy. Pancreatic adenocarcinoma is a lethal condition with a rising incidence, predicted to become the second leading cause of cancer death in some regions. It often presents at an advanced stage, which contributes to poor five-year survival rates of 2%-9%, ranking firmly last amongst all cancer sites in terms of prognostic outcomes for patients. Better understanding of the risk factors and symptoms associated with this disease is essential to inform both health professionals and the general population of potential preventive and/or early detection measures. The identification of high-risk patients who could benefit from screening to detect pre-malignant conditions such as pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms and mucinous cystic neoplasms is urgently required, however an acceptable screening test has yet to be identified. The management of pancreatic adenocarcinoma is evolving, with the introduction of new surgical techniques and medical therapies such as laparoscopic techniques and neo-adjuvant chemoradiotherapy, however this has only led to modest improvements in outcomes. The identification of novel biomarkers is desirable to move towards a precision medicine era, where pancreatic cancer therapy can be tailored to the individual patient, while unnecessary treatments that have negative consequences on quality of life could be prevented for others. Research efforts must also focus on the development of new agents and delivery systems. Overall, considerable progress is required to reduce the burden associated with pancreatic cancer. Recent, renewed efforts to fund large consortia and research into pancreatic adenocarcinoma are welcomed, but further streams will be necessary to facilitate the momentum needed to bring breakthroughs seen for other cancer sites. | Andrew McGuigan Paul Kelly Richard C Turkington Claire Jones Helen G Coleman R Stephen McCain | 2018 | World Journal of Gastroenterology2018，24，43： | 140 |
| 2 | Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4显示文摘最近的尖铁 glycoprotein (S) 鉴别中东呼吸症候群 coronavirus (MERS-CoV ) 指向细胞的受体, dipeptidyl peptidase 4 (DPP4 ) 。顺序比较和当模特儿的分析在病毒的尖铁上揭示了一个通常认为的受体绑定领域(RBD ) ,它调停这个相互作用。我们报导 3.0 Å MERS-CoV RBD 的决定水晶结构跳了到人的 DPP4 的细胞外的领域。我们的结果证明 MERS-CoV RBD 由一个核心和受体绑定子域组成。受体绑定子域与 DPP4 β 交往;推进器然而并非它的内在的 hydrolase 领域。MERS-CoV RBD 和相关 SARS-CoV RBD 分享他们的核心子域的结构的类似的高度,但是在受体绑定子域是尤其是分叉的。Mutagenesis 研究在为到 DPP4 和入口的病毒的绑定是批评的进目标房间的受体绑定子域识别了几关键残余。在在 MERS-CoV RBD 和 DPP4 之间的接口的原子细节提供病毒和受体相互作用的结构的理解,它能对 MERS-CoV 感染指导治疗学和疫苗的开发。 | Nianshuang Wang Xuanling Shi Liwei Jiang Senyan Zhang Dongli Wang Pei Tong Dongxing Guo Lili Fu Ye Cui Xi Liu Kelly C Arledge Ying-Hua Chen Linqi Zhang Xinquan Wang | 2013 | Cell Research2013，23，8： | 26 |
| 3 | 在血压控制不良的高血压患者中使用数字化干预的家庭和在线血压管理:随机对照试验显示文摘HOME BP试验(The home and online management and evaluation of blood pressure)的目的是评估在初级预防中结合自我监测和自我管理的数字化干预在高血压管理中的作用。研究者纳入英国76个治疗中心经过治疗但血压控制不好(>140/90 mm Hg, 1 mm Hg=0.133 kPa)并能上网的患者622例,进行自动确定主要终点的公开随机对照试验。 | McMa-nus RJ Little P Stuart B Morton K Raftery J Kelly J Bradbury K Zhang J Zhu S Murray E May CR Mair FS Michie S Smith P Band R Ogburn E AllenJ Rice C Nut-tall J Williams B Yardley L 陈嘉睿(译) 叶鹏(审校) | 2021 | 中华高血压杂志2021，29，5： | 15 |
| 4 | The wonders of BMP9:From mesenchymal stem cell differentiation,angiogenesis,neurogenesis,tumorigenesis,and metabolism to regenerative medicine显示文摘Although bone morphogenetic proteins(BMPs)initially showed effective induction of ectopic bone growth in muscle,it has since been determined that these proteins,as members of the TGF-b superfamily,play a diverse and critical array of biological roles.These roles include regulating skeletal and bone formation,angiogenesis,and development and homeostasis of multiple organ systems.Disruptions of the members of the TGF-b/BMP superfamily result in severe skeletal and extra-skeletal irregularities,suggesting high therapeutic potential from understanding this family of BMP proteins.Although it was once one of the least characterized BMPs,BMP9 has revealed itself to have the highest osteogenic potential across numerous experiments both in vitro and in vivo,with recent studies suggesting that the exceptional potency of BMP9 may result from unique signaling pathways that differentiate it from other BMPs.The effectiveness of BMP9 in inducing bone formation was recently revealed in promising experiments that demonstrated efficacy in the repair of critical sized cranial defects as well as compatibility with bone-inducing bio-implants,revealing the great translational promise of BMP9.Furthermore,emerging evidence indicates that,besides its osteogenic activity,BMP9 exerts a broad range of biological functions,including stem cell differentiation,angiogenesis,neurogenesis,tumorigenesis,and metabolism.This review aims to summarize our current understanding of BMP9 across biology and the body. | Sami Mostafa Mikhail Pakvasa Elam Coalson Allen Zhu Alex Alverdy Hector Castillo Jiaming Fan Alex Li Yixiao Feng Di Wu Elliott Bishop Scott Du Mia Spezia Alissa Li Ofir Hagag Alison Deng Winny Liu Mingyang Li Sherwin S·Ho Aravind Athiviraham Michael J·Lee Jennifer Moriatis Wolf Guillermo A·Ameer Hue H·Luu Rex C·Haydon Jason Strelzow Kelly Hynes Tong-Chuan He Russell R·Reid | 2019 | Genes & Diseases2019，6，3： | 15 |
| 5 | Hematopoietic stem cell-derived adipocytes and fibroblasts in the tumor microenvironment显示文摘The tumor microenvironment(TME) is complex and constantly evolving. This is due, in part, to the crosstalk between tumor cells and the multiple cell types that comprise the TME, which results in a heterogeneous population of tumor cells and TME cells. This review will focus on two stromal cell types, the cancerassociated adipocyte(CAA) and the cancer-associated fibroblast(CAF). In the clinic, the presence of CAAs and CAFs in the TME translates to poor prognosis in multiple tumor types. CAAs and CAFs have an activated phenotype and produce growth factors, inflammatory factors, cytokines, chemokines, extracellular matrix components, and proteases in an accelerated and aberrant fashion. Through this activated state, CAAs and CAFs remodel the TME, thereby driving all aspects of tumor progression, including tumor growth and survival, chemoresistance, tumor vascularization, tumor invasion, and tumor cell metastasis. Similarities in the tumorpromoting functions of CAAs and CAFs suggest that a multipronged therapeutic approach may be necessary to achieve maximal impact on disease. While CAAs and CAFs are thought to arise from tissues adjacent to the tumor, multiple alternative origins for CAAs and CAFs have recently been identified. Recent studies from our lab and others suggest that the hematopoietic stem cell, through the myeloid lineage, may serve as a progenitor for CAAs and CAFs. We hypothesize that the multiple origins of CAAs and CAFs may contribute to the heterogeneity seen in the TME. Thus, a better understanding of the origin of CAAs and CAFs, how this origin impacts their functions in the TME, and thetemporal participation of uniquely originating TME cells may lead to novel or improved anti-tumor therapeutics. | Ying Xiong Lindsay T Mc Donald Dayvia L Russell Ryan R Kelly Katie R Wilson Meenal Mehrotra Adam C Soloff Amanda C LaRue | 2015 | World Journal of Stem Cells2015，7，2： | 6 |
| 6 | Role of endoscopic vacuum therapy in the management of gastrointestinal transmural defects显示文摘A gastrointestinal(GI) transmural defect is defined as total rupture of the GI wall,and these defects can be divided into three categories: perforations,leaks,and fistulas. Surgical management of these defects is usually challenging and may be associated with high morbidity and mortality rates. Recently,several novel endoscopic techniques have been developed,and endoscopy has become a firstline approach for therapy of these conditions. The use of endoscopic vacuum therapy(EVT) is increasing with favorable results. This technique involves endoscopic placement of a sponge connected to a nasogastric tube into the defect cavity or lumen. This promotes healing via five mechanisms,including macrodeformation,microdeformation,changes in perfusion,exudate control,and bacterial clearance,which is similar to the mechanisms in which skin wounds are treated with commonly employed wound vacuums. EVT can be used in the upper GI tract,small bowel,biliopancreatic regions,and lower GI tract,with variable success rates and a satisfactory safety profile. In this article,we review and discuss the mechanism of action,materials,techniques,efficacy,and safety of EVT in the management of patients with GI transmural defects. | Diogo Turiani Hourneaux de Moura Bruna Furia Buzetti Hourneaux de Moura Michael A Manfredi Kelly E Hathorn Ahmad N Bazarbashi Igor Braga Ribeiro Eduardo Guimaraes Hourneaux de Moura Christopher C Thompson | 2019 | World Journal of Gastrointestinal Endoscopy2019，11，5： | 6 |
| 7 | 循证医学在急诊医疗中的局限性显示文摘 | A M Kelly C Horsley 冯丽洁 | 2001 | 中国危重病急救医学2001，13，10： | 6 |
| 8 | Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies显示文摘在地岬基因的 Oncogenic 变化在人的癌症是很普通的,导致有描绘得好的选择优点,而且不太听说得好的危险的房间。我们执行了一幅大规模 loss-of-function 屏幕识别被转变 KRAS 的结肠癌房间,然而并非由缺乏这 oncogene 的衍生物要求的基因。最高得分的基因然后在 KRAS 变异、野类型的癌症房间的一块更大的面板被测试。表示 oncogenic KRAS 的癌症房间被发现高度依赖于抄写因素 GATA2 和 DNA 复制开始管理者 CDC6。与已知的目标用许多药扩大这分析,我们发现有变异的 KRAS 的癌症房间与 topoisomerase 抑制显示出选择嗜好到 proteasome 功能,以及合成致命性。联合指向引起的这些功能改善了相对野类型的房间 KRAS 变异的房间杀死。这些观察建议新奇目标和在地岬变异的癌症为最佳的效果联合存在治疗的新方法,它传统地被看作对治疗高度倔强。 | Michael Steckel Miriam Molina-Arcas Britta Weigelt Michaela Marani Patricia H Warne Hanna Kuznetsov Gavin Kelly Becky Saunders Michael Howell Julian Downward David C Hancock | 2012 | Cell Research2012，22，8： | 5 |
| 9 | Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus显示文摘AIM:To assess tumour regression grade(TRG)and lymph node downstaging to help define patients who benefit from neoadjuvant chemotherapy.METHODS:Two hundred and eighteen consecutive patients with adenocarcinoma of the esophagus or gastro-esophageal junction treated with surgery alone or neoadjuvant chemotherapy and surgery between 2005and 2011 at a single institution were reviewed.Triplet neoadjuvant chemotherapy consisting of platinum,fluoropyrimidine and anthracycline was considered for operable patients(World Health Organization performance status≤2)with clinical stage T2-4 N0-1.Response to neoadjuvant chemotherapy(NAC)was assessed using TRG,as described by Mandard et al.In addition lymph node downstaging was also assessed.Lymph node downstaging was defined by cN1 at diagnosis:assessed radiologically(computed tomography,positron emission tomography,endoscopic ultrasonography),then pathologically recorded as N0 after surgery;ypN0 if NAC given prior to surgery,or pN0if surgery alone.Patients were followed up for 5 years post surgery.Recurrence was defined radiologically,with or without pathological confirmation.An association was examined between t TRG and lymph node downstaging with disease free survival(DFS)and a comprehensive range of clinicopathological characteristics.RESULTS:Two hundred and eighteen patients underwent esophageal resection during the study interval with a mean follow up of 3 years(median follow up:2.552,95%CI:2.022-3.081).There was a 1.8%(n=4)inpatient mortality rate.One hundred and thirty-six(62.4%)patients received NAC,with 74.3%(n=101)of patients demonstrating some signs of pathological tumour regression(TRG 1-4)and 5.9%(n=8)having a complete pathological response.Forty four point one percent(n=60)had downstaging of their nodal disease(cN1 to ypN0),compared to only 15.9%(n=13)that underwent surgery alone(pre-operatively overstaged:cN1 to pN0),(P<0.0001).Response to NAC was associated with significantly increased DFS(mean DFS;TRG 1-2:5.1years,95%CI:4.6-5.6 vs TRG 3-5:2.8 years,95%CI:2.2-3.3,P<0.0001).Nodal down-staging conferred a significant DFS advantage for those patients with a poor primary tumour response to NAC(median DFS;TRG 3-5 and nodal down-staging:5.533 years,95%CI:3.558-7.531 vs TRG 3-5 and no nodal down-staging:1.114 years,95%CI:0.961-1.267,P<0.0001).CONCLUSION:Response to NAC in the primary tumour and in the lymph nodes are both independently associated with improved DFS. | Fergus Noble Luke Nolan Adrian C Bateman James P Byrne Jamie J Kelly Ian S Bailey Donna M Sharland Charlotte N Rees Timothy J Iveson Tim J Underwood Andrew R Bateman | 2013 | World Journal of Gastroenterology2013，19，48： | 4 |
| 10 | 长沙市甲基苯丙胺使用情况“应答者驱动抽样”流行病学调查显示文摘目的:了解长沙市甲基苯丙胺使用的流行情况。方法:采用同伴驱动抽样(respondent-driven sampling,RDS),通过自拟问卷对长沙市最近3个月内使用过甲基苯丙胺的成年人进行抽样调查。结果:接受调查的129人以男性、汉族、有伴侣(包括配偶、男女朋友及同居者)、初高中学历、处于就业状态、年收入较高者为主;平均年龄为29.0 a±s7.8 a(最小18 a,最大48 a);102人进行过HIV抗体检测,皆为阴性;有94(72.9%)人曾使用过其他非法成瘾性物质包括k粉、摇头丸、海洛因、大麻、丁丙诺啡、曲马多、美沙酮及安定;尚未发现使用可卡因及快克者。长沙市甲基苯丙胺以冰和麻古两种形式存在并被使用。使用方式全为冰壶抽吸,使用场所均为私人场所(家里、宾馆及出租房)。最近三个月内甲基苯丙胺的平均使用天数为21.4 d±s31.3 d(中位数10 d),冰毒的平均用量为每次0.3 g,麻古3.8片。甲基苯丙胺的可及性很强,大多数人(87/126,69.0%)都能'比较容易或非常容易'地获取。使用甲基苯丙胺常见的原因有:吸毒同伴的存在、追求刺激、以及为了摆脱不良情绪状态等,很少有人用来减肥。使用甲基苯丙胺产生的不良后果主要包括对使用者的饮食、体重、健康、经济、情绪的影响以及家庭关系的伤害。结论:甲基苯丙胺在长沙易于获得、在同伴间广为传播,其使用对使用者本人及其家庭带来了严重的危害;因此相关部门有必要采取截断毒品来源、开展相关的禁毒宣传措施。 | 张官柏 刘铁桥 郝伟 Brian C Kelly 王济川 胡红星 曾敏 柳红 | 2011 | 中国药物依赖性杂志2011，20，4： | 4 |
| 11 | Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study显示文摘 | Timothy Iveson Ross C Donehower Irina Davidenko Sergey Tjulandin Andrzej Deptala Mark Harrison Somanath Nirni Kuntegowdanahalli Lakshmaiah Anne Thomas Yizhou Jiang Min Zhu Rui Tang Abraham Anderson Sarita Dubey Kelly S Oliner Elwyn Loh | 2014 | Lancet Oncology2014，，9： | 3 |
| 12 | Cancer-related inflammation and treatment effectiveness显示文摘 | Connie I Diakos Kellie A Charles Donald C McMillan Stephen J Clarke | 2014 | Lancet Oncology2014，，： | 3 |
| 13 | Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians显示文摘 | Getchell Jane P Wroblewski Kelly E DeMaria Alfred Bean Christine L Parker Monica M Pandori Mark Dufour D Robert Busch Michael P Brecher Mark E Meyer William A Pesano Rick L Teo Chong-Gee Beckett Geoffrey A Araujo Aufra C Branson Bernard M D | 2013 | MMWR. Morbidity and Mortality Weekly Report2013，，18： | 3 |
| 14 | SLC26A4 mutation testing for hearing loss associated with enlargement of the vestibular aqueduct显示文摘Pendred syndrome(PS) is characterized by autosomal recessive inheritance of goiter associated with a defect of iodide organification, hearing loss, enlargement of the vestibular aqueduct(EVA), and mutations of the SLC26A4 gene. However, not all EVA patients have PSor SLC26A4 mutations. Two mutant alleles of SLC26A4 are detected in 1/4 of North American or European EVA populations, one mutant allele is detected in another 1/4 of patient populations, and no mutations are detected in the other 1/2. The presence of two mutant alleles of SLC26A4 is associated with abnormal iodide organification, increased thyroid gland volume, increased severity of hearing loss, and bilateral EVA. The presence of a single mutant allele of SLC26A4 is associated with normal iodide organification, normal thyroid gland volume, less severe hearing loss and either bilateral or unilateral EVA. When other underlying correlations are accounted for, the presence of a cochlear malformation or the size of EVA does not have an effect on hearing thresholds. This is consistent with observations of an Slc26a4 mutant mouse model of EVA in which hearing loss is independent of endolymphatic hydrops or inner ear malformations. Segregation analyses of EVA in families suggest that the patients carrying one mutant allele of SLC26A4 have a second, undetected mutant allele of SLC26A4, and the probability of a sibling having EVA is consistent with its segregation as an autosomal recessive trait. Patients without any mutations are an etiologically heterogeneous group in which siblings have a lower probability of having EVA. SLC26A4 mutation testing can provide prognostic information to guide clinical surveillance and management, as well as the probability of EVA affecting a sibling. | Taku Ito Julie Muskett Parna Chattaraj Byung Yoon Choi Kyu Yup Lee Christopher K Zalewski Kelly A King Xiangming Li Philine Wangemann Thomas Shawker Carmen C Brewer Seth L Alper Andrew J Griffith | 2013 | World Journal of Otorhinolaryngology2013，3，2： | 2 |
| 15 | Characterization Study of Diamond and Diamond-like Carbon显示文摘 | Dowling D P Ahern M J Kelly T C | 1992 | Surface and Coating Technology1992，53，： | 2 |
| 16 | Correlation between bovine milksomatic cell count and polymorphonuclear leukocyte level for samples of bulkmilk and milk from individual cows显示文摘 | Kelly A L Tiernan D O'Sullivan C | 2000 | Journal of Dairy Science2000，83，2： | 1 |
| 17 | Structural testing of concurrent programs显示文摘 | Taylor R N Levine D L Kelly C D | 1992 | IEEE Trans Softw Eng1992，18，3： | 1 |
| 18 | The causes and diagnosis of influenza-like illness 显示文摘 | Kelly H Birch C | 2004 | Aust Fam Physician2004，33，5： | 1 |
| 19 | Concentrations and fluxes of dissolved biogenic gases (DMS,CH4,CO,CO2) in the equatorial Pacific during the SAGA-3 experiment显示文摘 | Bates T S Kelly K C Johnson J E | 1993 | J Geophys Res1993，98，16： | 1 |
| 20 | Structure of the alpha-actinin-vinculin head domain complex determined by cryo-electron microscopy显示文摘 | Kelly DF Taylor DW Bakolitsa C | 2006 | J Mol Biol2006，357，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员